To the Editor:
The number of nucleotide mutations in the "y-and 'y-globin gene promoter segments that are associated with an increased production of hemoglobin (Hb) with either "y or 'y chains is steadily increasing. In our continued search for such mutations we detected a C -+ T substitution at position -114 of the "y-globin gene in two young black males who had been followed for over 10 years. Their hematologic data were completely normal; no microcytosis or hypochromia was evident. Hb composition data are listed in Table 1 . Both had a persistent elevation of Hb F (3% to 5%); this Hb F contained mainly Ay chains. Parents and other family members were not available for study.
Blood was collected in EDTA and DNA was extracted from the white blood cells by the method of Poncz et a1. 6 The DNA was amplified asymmetrically' with primers and buffers as previously DNA sequencing was performed by the method of Sanger et a]."' Figure 1 illustrates part of a film of a sequencing gel showing a C -+ T mutation at position -114 relative to the Cap site of the "y-globin gene. This mutation was confirmed by dot-blot analysis using "P-labeled synthetic oligonucleotide probes (data not shown).
The C + T mutation occurs in the distal CCAAT box (positions -111 to -115) present in a region that serves as a binding site for ubiquitous and evthroid-specific nuclear proteins.'' Point mutations in such an area are believed to be responsible for the observed phenotype with varying elevations of Hb F because of an altered binding of such protein(s). Fucharoen et all2 recently identified an identical mutation (C -T) at nucleotide -114 of the 'y-globin gene and observed that binding of the ubiquitous factor CP1 was absent, whereas that of any erythroid-specific factor was not altered. As the sequences of these ' y and "y promoter elements are essentially the same, one can assume that a similar decrease has occurred in the specific binding of CP1 to the "y promoter with the altered CC(-,T)AAC box found in our two patients. Fucharoen et all2 stress the apparent importance of an intact CCAAT box for the binding of the CP1 factor and have studies in progress examining how this C -, T mutation may affect the 'y-(or "y-) globin gene expression.
The Hb F level in heterozygotes for the -114 C -T ('7) mutation (11% to 14%) is reported to be two to three times that of our patients with the same mutation in the "y promoter (3% to 5%). It is important to note that methodology for Hb F quantitation in the two studies was quite different. The DEAE-cellulose chromatographic procedure used by Fucharoen et al is rather inaccurate for quantitating small amounts of Hb F because Hb F and Hb A,, are often eluted at the same location in the chromato- gram. If that was the case in the Fucharoen study, it will explain the high Hb F levels (5.6%, 5.9%) reported for the normal members of their Japanese farmly and will reduce the Hb F levels in the hereditary persistence of fetal hemoglobin (HPFH) ('y) heterozygotes to values comparable with those found in our ("y) heterozygotes. 
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